Literature DB >> 15040657

Tenofovir-related nephrotoxicity: case report and review of the literature.

Christopher W James1, Mary C Steinhaus, Susan Szabo, Robert M Dressier.   

Abstract

Tenofovir is a nucleotide reverse transcriptase inhibitor for treatment of human immunodeficiency virus (HIV) infection. Several cases of renal failure associated with tenofovir therapy recently have been reported. A 54-year-old man with HIV experienced decreasing renal function and Fanconi's syndrome secondary to tenofovir therapy. His condition gradually improved after discontinuation of the drug. The available medical literature for reported cases of tenofovir-related nephrotoxicity indicates that this complication is apparently rare. However, our case report and literature review underscore the importance of monitoring renal function when treating patients with any nucleotide reverse transcriptase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15040657     DOI: 10.1592/phco.24.4.415.33182

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  16 in total

1.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Authors:  Jérôme Tourret; Gilbert Deray; Corinne Isnard-Bagnis
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

3.  Acquired Fanconi's syndrome associated with tenofovir therapy.

Authors:  George Mathew; Stephen J Knaus
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

4.  A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.

Authors:  Amber Dahlin; Matthias Wittwer; Melanie de la Cruz; Jonathan M Woo; Rujuta Bam; Valeska Scharen-Guivel; John Flaherty; Adrian S Ray; Tomas Cihlar; Samir K Gupta; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

Review 5.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters.

Authors:  James J Kohler; Seyed H Hosseini; Elgin Green; Allison Abuin; Tomika Ludaway; Rodney Russ; Robert Santoianni; William Lewis
Journal:  Lab Invest       Date:  2011-03-14       Impact factor: 5.662

7.  Tenofovir nephrotoxicity: 2011 update.

Authors:  Beatriz Fernandez-Fernandez; Ana Montoya-Ferrer; Ana B Sanz; Maria D Sanchez-Niño; Maria C Izquierdo; Jonay Poveda; Valeria Sainz-Prestel; Natalia Ortiz-Martin; Alejandro Parra-Rodriguez; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  AIDS Res Treat       Date:  2011-06-07

8.  Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India.

Authors:  Ketan K Patel; Atul K Patel; Rajiv R Ranjan; Apurva R Patel; Jagdish K Patel
Journal:  Indian J Sex Transm Dis AIDS       Date:  2010-01

Review 9.  Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

Authors:  Yohannes Hagos; Natascha A Wolff
Journal:  Toxins (Basel)       Date:  2010-08-09       Impact factor: 4.546

10.  Review of tenofovir-emtricitabine.

Authors:  Saba Woldemichael Masho; Cun-Lin Wang; Daniel E Nixon
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.